Results

Total Results: 2,279 records

Showing results for "factor".

141. Rheumatoid-Arthritis-Medicine Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_executive.pdf
     April 01, 2012 - leflunomide, methotrexate [MTX], and sulfasalazine), and biologic DMARDs (five anti-tumor necrosis factor … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Abbreviations ACR American College of Rheumatology Anti-TNF Anti-tumor necrosis factor drugs CDER Center

142. Dietary Proteins | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/dietary-proteins?page=2
     September 19, 2012 - Future Research Needs Research Report September 13, 2012 Data Points #15: Prognostic factor

143. Dietary Proteins | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/dietary-proteins?page=1
     February 11, 2014 - Presentation Archived August 14, 2013 Effectiveness and Off-Label Use of Recombinant Factor

144. Immune System and Disorders | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/immune-system-and-disorders?page=1
     December 10, 2013 - Rhinitis Systematic Review Archived March 7, 2012 Antinuclear Antibody, Rheumatoid Factor

145. Surgery | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/surgery?page=2
     June 12, 2013 - Antibiotic Therapy Research Report September 13, 2012 Data Points #15: Prognostic factor

146. Bladder-Cancer-Non-Muscle-Invasive Research-Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/bladder-cancer-non-muscle-invasive_research-protocol.pdf
     July 21, 2014 - taking into account diagnostic testing, management, and long term follow up.4 The most common risk factor … using techniques such as fluorescence in situ hybridization [FISH] assay or mRNA); fibroblast growth factor … cytokeratin fragments (e.g., CYFRA 21-1, TPA, TPS); survivin; telomerase; vascular endothelial growth factor … matrix protein or nmp22 or fluorescence in situ hybrid$ or (fish adj assay$) or fibroblast growth factor … cyfra 21-1 or (cytokerat$ adj3 (tpa or tps)) or survivin or telomeras$ or vascular endothelial growth factor

147. Heart Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/heart-diseases?page=3
     February 08, 2011 - October 29, 2010 Utilization and Clinical Data on In-Hospital Off-Label Uses of Recombinant Factor

148. Vascular Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/vascular-diseases?page=3
     February 17, 2011 - October 29, 2010 Utilization and Clinical Data on In-Hospital Off-Label Uses of Recombinant Factor

149. 1. Which patients benefit the most from MTM services? 1.1. Which factors, or combinations of factors, are most predictive of the clinical benefit of MTM services? 1.1.1. Disease factors (e.g., diabetes vs COPD ; multi-morbidity vs single… | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/1-which-patients-benefit-the-most-from-mtm-services-11-which-factors-or-combinations-of-factors-are-most-predictive-of-the-clinical-benefit-of-mtm-services-111-disease-factors-eg-diabetes-vs-copd-multi-morbidity-vs-single-di
     November 01, 2017 - Another significant factor that has prompted this recommendation to the Effective Health Care Program

150. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
     March 01, 2013 - Randomized Controlled Trial; SCEPC: Southern California Evidence-based Practice Center; TNF: Tumor Necrosis Factor … Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection … and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor … Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including … Randomized Controlled Trial; SCEPC: Southern California Evidence-based Practice Center; TNF: Tumor Necrosis Factor

151. Evidence Report on the (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/vte-protocol-8-4-10.pdf
     February 01, 2008 - injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … what is the relative impact of injectable antithrombotic agents (LMWH vs. unfractionated heparin vs. factor … Factor Xa Inhibitors Rivaroxiban (Xarelto®) Ortho-McNeil- Janssen Investigational drug, not … methods of thromboprophylaxis versus control or compare injectable antithrombotic agents (LMWH, UFH, factor

152. Evidence Report on the (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/blood-clots-hip-knee-surgery_research-protocol.pdf
     February 01, 2008 - injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … what is the relative impact of injectable antithrombotic agents (LMWH vs. unfractionated heparin vs. factor … Factor Xa Inhibitors Rivaroxiban (Xarelto®) Ortho-McNeil- Janssen Investigational drug, not … methods of thromboprophylaxis versus control or compare injectable antithrombotic agents (LMWH, UFH, factor

153. Simulation-Based Comparison of Methods and Meta-Analysis of Proportions and Rates (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/metanalysis-proportion-rate-comparison_research.pdf
     November 01, 2013 - The correction factor is an analytic choice and not a simulation parameter; however it is listed here … , or correction factor for short. … Since for untransformed proportions, the correction factor is needed only in the variance estimate, … of the correction factor and the sample size of the study. … , and increases as the correction factor gets larger.

154. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
     October 01, 2015 - Esbriet®) is a synthetic pyridone analogue reported to inhibit the synthesis of transforming growth factor … receptors purportedly involved in the pathogenesis of IPF, including vascular endothelial growth factor … receptor 2 (VEGFR2), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor … receptor kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), fibroblast growth … factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).

155. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/opioids-older-adults/report
     January 01, 2022 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

156. Rapid Response_Linking Dental Services to Treatment Outcomes for Chronic Kidney Disease: A Rapid Response Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/treatment-outcomes-chronic-kidney-rapid-research.pdf
     November 01, 2024 - Indeed, recent findings have identified that periodontitis is a risk factor for eGFR decline, and dental … ND: no dialysis; PD: peritoneal dialysis; TIBC: Total iron binding capacity; TNF-α: Tumor Necrosis Factor … treatment; OHI: Oral hygiene instruction; RCT: randomized controlled trial; TNF-α: Tumor Necrosis Factor … treatment; OHI: Oral hygiene instruction; RCT: randomized controlled trial; TNF-α: Tumor Necrosis Factor … Effects of Non-Surgical Periodontal Therapy on Serum Inflammatory Factor High-Sensitive C- Reactive

157. Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/mental-illness-heart/research
     December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

158. Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/bladder-cancer-non-muscle-invasive/research-protocol
     December 01, 2020 - taking into account diagnostic testing, management, and long term follow up. 4 The most common risk factor … using techniques such as fluorescence in situ hybridization [FISH] assay or mRNA); fibroblast growth factor … cytokeratin fragments (e.g., CYFRA 21-1, TPA, TPS); survivin; telomerase; vascular endothelial growth factor … nuclear matrix protein or nmp22 or fluorescence in situ hybrid$ or (fish adj assay$) or fibroblast growth factor … cyfra 21-1 or (cytokerat$ adj3 (tpa or tps)) or survivin or telomeras$ or vascular endothelial growth factor

159. Nonemergent Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Stable Ischemic Heart Disease: A Rapid Response Literature Review | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/heart-disease/research
     August 01, 2023 - Another factor that complicates comparison is that the meta-analyses often included data from CABG and

160. Data Points Publication Series | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/data-points-series/series-overview
     October 01, 2019 - ductal carcinoma in situ or early invasive breast cancer (PDF) 621 kB Data Points #15: Prognostic factor